SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant x Filed by a Party Other Than the Registrant ¨
Check the Appropriate Box:
|¨||Preliminary Proxy Statement|
|¨||Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2))|
|¨||Definitive Proxy Statement|
|x||Definitive Additional Materials|
|¨||Soliciting Material Pursuant to §240.14a-12|
|(Name of Registrant as Specified In Its Charter)|
|(Name of Person(s) Filing Proxy Statement, if other than the Registrant)|
|Payment of filing fee (Check the appropriate box):|
|x||No fee required.|
|¨||Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11|
Title of each class of securities to which transaction applies:
Aggregate number of securities to which transaction applies:
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
Proposed maximum aggregate value of transaction:
|(5)||Total fee paid:|
|¨||Fee paid previously with preliminary materials.|
|¨||Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.|
Amount Previously Paid:
Form, Schedule or Registration Statement No.:
235 East 42nd Street, New York, NY 10017
Dear Pfizer Shareholder:
On April 26, 2012, Pfizer Inc. will hold its Annual Meeting of Shareholders. I am writing to ask for your support at our Annual Meeting by voting your shares; your vote is needed and valued. With the Annual Meeting only a short time away, please act today to be sure your shares are voted in accordance with your wishes.
As I noted in my letter To Our Shareholders, our financial performance in 2011 was strong. We met or exceeded every component of our full-year financial guidance, despite the headwinds from a challenging global business environment and the reality of absorbing about $5 billion in revenue declines due to changes in the patent status of some products, most notably Lipitor in the U.S. In addition, we reduced our operating expenses and took several steps to allocate capital in ways that resulted in greater shareholder value. We returned more than $15 billion in capital to shareholders through dividend payments of over $6 billion and stock repurchases of approximately $9 billion. I remain confident that we are taking the right actions to create value for you, and for all of our shareholders. You may view the full text of my letter* in the Proxy Statement at www.pfizer.com/proxy.
If you have already voted, thank you for your prompt response. If not, you can vote by telephone, Internet or mail. For your convenience, a duplicate proxy/voting instruction card and return envelope are enclosed, along with telephone and Internet voting instructions. In the event that two proxies/voting instruction forms are received from you, the one with the latest date will be counted.
I appreciate your continued investment in Pfizer and your consideration of the matters to be presented at this years Annual Meeting.
Thank you for voting.
|Ian C. Read|
|Chairman and CEO|
|*||Not part of our proxy solicitation materials|